The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer
Jeffrey Howard Lipton
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Teva
Research Funding - Bristol-Myers Squibb; Novartis
Goh Yeow Tee
Consultant or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis
Honoraria - Bristol-Myers Squibb; Janssen; Novartis
Research Funding - Janssen; Novartis
Luis Felipe Casado
No relevant relationships to disclose
Andrey Zaritskey
No relevant relationships to disclose
Philipp D. le Coutre
Research Funding - Novartis
Ladan Duvillie
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dmitri Pavlov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Athena Maria Countouriotis
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jennifer Byrne
Honoraria - Pfizer